Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7525-7545

  Kümmerle, Arthur E ^a,d   Schmitt, Martine ^b   Cardozo, Suzana V S ^a,c   Lugnier, Claire ^b   Villa, Pascal ^b   Lopes, Alexandra B ^a   Romeiro, Nelilma C ^a   Justiniano, Hélène ^b   Martins, Marco A ^c   Fraga, Carlos A M ^a   Bourguignon, Jean Jacques ^b   Barreiro, Eliezer J ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d FEDERAL RURAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AWD 12281; CLOMILAST; HYDRAZONE DERIVATIVE; LIPOPOLYSACCHARIDE; N ACYLHYDRAZONE; PHOSPHODIESTERASE IV INHIBITOR; QUINAZOLINE DERIVATIVE; ROLIPRAM; TOFIMILAST; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; ZARDAVERINE;

ARTICLE; CONFORMATIONAL TRANSITION; CRYSTALLIZATION; DRUG CONFORMATION; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG COMPLIANCE; LUNG RESISTANCE; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RESPIRATORY TRACT ALLERGY; THREE DIMENSIONAL IMAGING;

ADMINISTRATION, ORAL; ANIMALS; DRUG DESIGN; FEMALE; HUMANS; HYDRAZONES; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHOSPHODIESTERASE 4 INHIBITORS; PNEUMONIA;

EID: 84866325655     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300514y     Document Type: Article

References (96)

1. Beavo, J. A. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms Physiol. Rev. 1995, 75, 725-748
2. Conti, M.; Jin, S. L. The molecular biology of cyclic nucleotide phosphodiesterases Prog. Nucleic Acid Res. Mol. Biol. 1999, 63, 1-38
3. Houslay, M. D. Adaptation in cyclic AMP signalling processes: A central role for cyclic AMP phosphodiesterases Semin. Cell Dev. Biol. 1998, 9, 161-167 (Pubitemid 128352267)
4. Keravis, T.; Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: Benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments Br. J. Pharmacol. 2012, 165, 1288-1305
5. Francis, S. H.; Turko, I. V.; Corbin, J. D. Cyclic nucleotide phosphodiesterases: Relating structure and function Nucleic Acid Res. Mol. Biol. 2000, 65, 1-52
6. Manallack, D.; Hughes, R.; Thompson, P. The next generation of phosphodiesterase inhibitors: Structural clues to ligand and substrate selectivity of phosphodiesterases J. Med. Chem. 2005, 48, 3449-3462 (Pubitemid 40664094)
7. Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents Pharmacol. Ther. 2006, 109, 366-398 (Pubitemid 43132818)
8. Menniti, F. S.; Faraci, W. S.; Schmidt, C. J. Phosphodiesterases in the CNS: Targets for drug development Nat. Rev. Drug Discovery 2006, 5, 660-670 (Pubitemid 44151604)
9. Houslay, M. D.; Schafer, P.; Zhang, K. Y. J. Keynote review: Phosphodiesterase-4 as a therapeutic target Drug Discovery Today 2005, 10, 1503-1519 (Pubitemid 41527193)
10. Wang, D. G; Deng, C. J.; Bugaj-Gaweda, B.; Kwan, M.; Gunwaldsen, C.; Leonard, C.; Xin, X. N.; Hu, Y. H.; Unterbeck, A.; De Vivo, M. Cloning and characterization of novel PDE4D isoforms PDE4D6 and PDE4D7 Cell. Signalling 2003, 15, 883-891 (Pubitemid 36776662)
11. Castro, A.; Jerez, M. J.; Gil, C.; Martinez, A. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterases inhibitors Med. Res. Rev. 2005, 25, 229-244 (Pubitemid 40299847)
12. Banner, K. H.; Trevethick, M. A. PDE4 inhibition: A novel approach for the treatment of inflammatory bowel disease Trends Pharmacol. Sci. 2004, 25, 430-436 (Pubitemid 38981559)
13. Draheim, R.; Egerland, U.; Rundfeldt, C. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N -(3,5-dichloro-pyrid-4-yl)-[1-(4- fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations J. Pharmacol. Exp. Ther. 2004, 308, 555-563 (Pubitemid 38134217)
14. Jeffery, P. Phosphodiesterase 4-selective inhibition: Novel therapy for the inflammation of COPD Pulm. Pharmacol. Ther. 2005, 18, 9-17 (Pubitemid 39647748)
15. O'Donnell, J. M.; Zhang, H. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4) Trends Pharmacol. Sci. 2004, 25, 158-163 (Pubitemid 38264507)
16. Spina, D. The potential of PDE4 inhibitors in respiratory disease Curr. Drug Targets: Inflammation Allergy 2004, 3, 231-236 (Pubitemid 39206651)
17. O'Byrne, P. M.; Gauvreau, G. Phosphodiesterase-4 inhibition in COPD Lancet 2009, 374, 665-667
18. Pages, L.; Gavalda, A.; Lehner, M. D. PDE4 inhibitors: A review of current developments (2005-2009) Expert Opin. Ther. Pat. 2009, 19, 1501-1519
19. Page, C. P.; Spina, D. Selective PDE inhibitors as novel treatments for respiratory diseases Curr. Opin. Pharmacol. 2012, 12, 1-12
20. Kodimuthali, A.; Jabaris, S. S. L.; Pal, M. Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease J. Med. Chem. 2008, 51, 5471-5489
21. Amschler, H. Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors. US Patent 5,712,298, 1998.
22. Fabbri, L. M.; Calverley, P. M. A.; Izquierdo-Alonso, J. L.; Bundschuh, D. S.; Brose, M.; Martinez, F. J.; Rabe, K. F. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: Two randomised clinical trials Lancet 2009, 374, 695-703
23. Hatzelmann, A.; Morcillo, E. J.; Lungarella, G.; Adnot, S.; Sanjar, S.; Beume, R.; Schudt, C.; Tenor, H. The preclinical pharmacology of roflumilast-A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease Pulm. Pharmacol. Ther. 2010, 23, 235-256
24. Calverley, P. M. A.; Rabe, K. F.; Goehring, U. M.; Kristiansen, S.; Fabbri, L. M.; Martinez, F. J. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials Lancet 2009, 374, 685-694
25. Duplantier, A. J.; Bachert, E.; Cheng, J.; Cohan, V.; Jenkinson, T.; Kraus, K.; McKechney, M.; Pillar, J.; Watson, J. SAR of a series of 5,6-dihydro-(9 H)-pyrazolo[3,4- c ]-1,2,4-triazolo[4,3-α]pyridines as potent inhibitors of human eosinophil phosphodiesterase J. Med. Chem. 2007, 50, 344-349 (Pubitemid 46147713)
26. Robichaud, A.; Stamatiou, P. B.; Jin, C.; Lachance, N.; MacDonald, D.; Laliberté, F.; Liu, S.; Huang, Z.; Conti, M.; Chan, C. C. Deletion of phosphodiesterase 4D in mice shortens alpha2-adrenoceptor-mediated anesthesia, a behavioural correlate of emesis J. Clin. Invest. 2002, 110, 1045-1052
27. Dal Piaz, V.; Giovannoni, M. P. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies Eur. J. Med. Chem. 2000, 35, 463-480 (Pubitemid 30395096)
28. Houslay, M. D.; Adams, D. R. Putting the lid on phosphodiesterase 4 Nat. Biotechnol. 2010, 28, 38-40
29. Giembycz, M. A. 4D or not 4D - the emetogenic basis of PDE4 inhibitors uncovered? Trends Pharmacol. Sci. 2002, 23, 548 (Pubitemid 35375796)
30. Giembycz, M. A.; Field, S. K. Roflumilast: The first in class phosphodiesterase 4 inhibitor approved for the treatment of COPD Drug Des., Dev. Ther. 2010, 4, 147-158
31. Fraga, C. A. M.; Barreiro, E. J. Medicinal chemistry of N -acylhydrazones: New lead-compounds of analgesic, antiinflammatory and antithrombotic drugs Curr. Med. Chem. 2006, 13, 167-198
32. Duarte, C. D.; Barreiro, E. J.; Fraga, C. A. M. Privileged structures: A useful concept for the rational design of new lead drugs candidates Mini-Rev. Med. Chem. 2007, 7, 1108-1119 (Pubitemid 350200217)
33. Fraga, C. A. M.; Barreiro, E. J. Cardiotônicos: Histórico e perspectivas de uma antiga e importante classe de agentes terapêuticos Quim. Nova 1996, 19, 182-189
34. Barreiro, E. J. Estratégia de simplificação molecular no planejamento racional de fármacos: A descoberta de novo agente cardioativo Quim. Nova 2002, 25, 1172-1180
35. Sudo, R. T.; Zapata-Sudo, G.; Barreiro, E. J. LASSBio 294, a novel cardionotropic agent, increases the calcium content in the sarcoplasmatic reticulum of saponin-skinned cardiac fibres Br. J. Pharmacol. 2001, 134, 603-613
36. Silva, C. L. M.; Noel, F.; Barreiro, E. J. Vasodilatory properties of LASSBio 294 and its dependence on cGMP increase Br. J. Pharmacol. 2002, 135, 293-298 (Pubitemid 34102124)
37. Dal Piaz, V.; Giovannoni, M.; Castellana, C.; Palacios, J.; Beleta, J.; Domenech, T.; Segarra, V. Heterocyclic-fused 3(2 H)-pyridazinones as potent and selective PDE IV inhibitors: Further structure-activity relationships and molecular modelling studies J. Med. Chem. 1997, 40, 1417-1421
38. Lima, L. M.; Barreiro, E. J. Bioisosterism, an useful strategy for molecular modification and drug design Curr. Med. Chem. 2005, 12, 23-49 (Pubitemid 40089827)
39. Kümmerle, A. E.; Raimundo, J. M.; Leal, C. M.; da Silva, G. S.; Balliano, T. L.; Pereira, M. A.; de Simone, C. A.; Sudo, R. T.; Zapata-Sudo, G.; Fraga, C. A.; Barreiro, E. J. Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N -acylhydrazone derivatives Eur. J. Med. Chem. 2009, 44, 4004-4009
40. Silva, A. G.; Zapata-Sudo, G.; Kummerle, A. E.; Fraga, C. A. M.; Barreiro, E. J.; Sudo, R. T. Synthesis and vasodilatory activity of new N -acylhydrazone derivatives, designed as LASSBio-294 analogues Bioorg. Med. Chem. 2005, 13, 3431-3437 (Pubitemid 40545797)
41. Yamada, S.; Morizono, D.; Yamamoto, K. Mild oxidation of aldehydes to the corresponding carboxylic acids and esters: Alkaline iodine oxidation revisited Tetrahedron Lett. 1992, 33, 4329-4332
42. Lima, P. C.; Lima, L. M.; da Silva, K. C. M.; Léda, P. H. O.; de Miranda, A. L. P.; Fraga, C. A. M.; Barreiro, E. J. Synthesis and analgesic activity of novel N -acylhydrazones and isosters, derived from natural safrole Eur. J. Med. Chem. 2000, 35, 187-203 (Pubitemid 30165683)
43. Lai, G.; Anderson, W. K. A simplified procedure for the efficient conversion of aromatic aldehydes into esters Synth. Commun. 1997, 27, 1281-1283 (Pubitemid 27186703)
44. Kaminski, J. J.; Bristol, J. A.; Puchalski, C.; Lovey, R. G.; Elliott, A. J.; Guzik, H.; Solomon, D. M.; Conn, D. J.; Domalski, M. S. Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2- a ]pyridines J. Med. Chem. 1985, 28, 876-892 (Pubitemid 15012494)
45. Ribeiro, I. G.; da Silva, K. C. M.; Parrini, S. C.; de Miranda, A. L. P.; Fraga, C. A. M.; Barreiro, E. J. Synthesis and antinociceptive properties of new structurally planned imidazo[1, 2- a ]pyridine 3-acylarylhydrazone derivatives Eur. J. Med. Chem. 1998, 33, 225-235 (Pubitemid 28188259)
46. Patel, J. M.; Dave, M. P.; Langalia, N. A.; Thaker, K. A. Studies on antitubercular agents preparation of 1-(4-methoxybenzoyl)-2-benzalhydrazine and 2-aryl-3-(4-methoxybenzamido)-5-carboxymethyl-4-thiazolidinone J. Indian Chem. Soc. 1985, 62, 254-255 (Pubitemid 17169771)
47. Kumar, P.; Narasimhan, B.; Sharma, D.; Judge, V.; Narang, R. Hansch analysis of substituted benzoic acid benzylidene/furan-2-yl-methylene hydrazides as antimicrobial agents Eur. J. Med. Chem. 2009, 44, 1853-1863
48. Kumar, D.; Narang, R.; Judge, V.; Kumar, D.; Narasimhan, B. Antimicrobial evaluation of 4-methylsulfanyl benzylidene/3-hydroxy benzylidene hydrazides and QSAR studies Med. Chem. Res. 2012, 21, 382-394
49. Karabatsos, G. J.; Taller, R. A. Structural studies by nuclear magnetic resonance. V. Phenylhydrazones J. Am. Chem. Soc. 1963, 85, 3624-3629
50. Palla, G.; Predieri, G.; Domiano, P.; Vignali, C.; Turner, W. Conformational behaviour and E / Z isomerization of N -acyl and N -aroylhydrazones Tetrahedron 1986, 42, 3649-3654
51. Palla, G.; Pelizzi, C.; Predieri, G.; Vignali, C. Conformational study on N -acylhydrazones of aromatic-aldehydes by NMR-spectroscopy Gazz. Chim. Ital. 1982, 112, 339-341
52. Barco, A.; Benetti, S.; Pollini, G. P. A facile alkylation of ethyl 2-oxocyclopentanecarboxylate Synthesis 1973, 316
53. Benstead, D. J.; Hulme, A. N.; McNab, H.; Wight, P. An efficient synthesis of substituted hydrazides Synlett 2005, 1571-1574 (Pubitemid 40922530)
54. Spivey, A. C.; McKendrick, J.; Srikaran, R.; Helm, B. A. Solid-phase synthesis of an A-B loop mimetic of the C epsilon 3 domain of human IgE: Macrocyclization by Sonogashira coupling J. Org. Chem. 2003, 68, 1843-1851 (Pubitemid 36511333)
55. Hellal, M.; Bourguignon, J.; Bihel, F. J. 6- endo-dig Cyclization of heteroarylesters to alkynes promoted by Lewis acid catalyst in the presence of Brönsted acid Tetrahedron Lett. 2008, 49, 62-65 (Pubitemid 350191886)
56. Lugnier, C.; Schoeffter, P.; Le Bec, A.; Strouthou, E.; Stoclet, J. C. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta Biochem. Pharmacol. 1986, 35, 1743-1751 (Pubitemid 16067796)
57. Tcheudji, J. F. K.; Lebeau, L.; Virmaux, N.; Maftei, C. G.; Cote, R. H.; Lugnier, C.; Schultz, P. Molecular organization of bovine rod cGMP-phosphodiesterase 6 J. Mol. Biol. 2001, 310, 781-791 (Pubitemid 32695695)
58. Keravis, T. M.; Wells, J. N.; Hardman, J. G. Cyclic nucleotide phosphodiesterase activities from pig coronary arteries. Lack of interconvertibility of major forms Biochim. Biophys. Acta 1980, 613, 116-129 (Pubitemid 10041368)
59. Barreiro, E. J.; Kümmerle, A. E.; Fraga, C. A. M. The methylation effect in medicinal chemistry Chem. Rev. 2011, 111, 5215-5246
60. Lagente, V.; Martin-Chouly, C.; Boichot, E.; Martins, M. A.; Silva, P. M. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases Mem. Inst. Oswaldo Cruz 2005, 100 (Suppl 1) 131-136 (Pubitemid 40685453)
61. Robichaud, A.; Savoie, C.; Stamatiou, P. B.; Tattersall, F. D.; Chan, C. C. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway Neuropharmacology 2001, 40, 262-269
62. Robichaud, A.; Savoie, C.; Stamatiou, P. B.; Lachance, N.; Jolicoeur, P.; Rasori, R.; Chan, C. C. Assessing the emetic potential of PDE4 inhibitors in rats Br. J. Pharmacol. 2002, 135, 113-118 (Pubitemid 34102104)
63. Williams, R. O.; Feldmann, M.; Maini, R. N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 9784-9788
64. Barnes, P. J. Cytokines as mediators of chronic asthma Am. J. Respir. Crit. Care Med. 1994, 150, 542-549
65. Renzetti, L. M.; Paciorek, P. M.; Tannu, S. A.; Rinaldi, N. C.; Tocker, J. E.; Wasserman, M. A.; Gater, P. R. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways J. Pharmacol. Exp. Ther. 1996, 278, 847-853 (Pubitemid 27167054)
66. Jin, S. L.; Conti, M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 7628-7633 (Pubitemid 34568742)
67. Hartman, D. A.; Ochalski, S. J.; Carlson, R. P. The effects of antiinflammatory and antiallergic drugs on cytokine release after stimulation of human whole blood by lipopolysaccharide and zymosan A Inflamm. Res. 1995, 44, 269-274
68. Heaslip, R. J.; Evans, D. Y. Emetic, central nervous system and pulmonary activities of rolipram in the dog Eur. J. Pharmacol. 1995, 286, 281-290
69. Lagente, V.; Martin-Chouly, C.; Boichot, E.; Martins, M. A.; Silva, P. M. R. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases Mem. Inst. Oswaldo Cruz 2005, 100, 131-136 (Pubitemid 40685453)
70. Harmsen, A. Role of alveolar macrophages in lipopolysaccharide-induced neutrophil accumulation Infect. Immun. 1988, 56, 1858-1863
71. Horn, R. G.; Collins, R. D. Fragmentation of granulocytes in pulmonary capillaries during development of the generalized Shwartzman reaction Lab. Invest. 1968, 19, 451-459
72. O'Malley, J.; Matesic, L. E.; Zink, M. C.; Strandberg, J. D.; Mooney, M. L.; De Maio, A.; Reeves, R. H. Comparison of acute endotoxin-induced lesions in A/J and C57BL/6J mice J. Hered. 1998, 89, 525-530 (Pubitemid 28560083)
73. Gonçalves de Moraes, V. L.; Vargaftig, B. B.; Lefort, J.; Meager, A.; Chignard, M. Effect of cyclo-oxygenase inhibitors and modulators of cyclic AMP formation on lipopolysaccharide-induced neutrophil infiltration in mouse lung Br. J. Pharmacol. 1996, 117, 1792-1796 (Pubitemid 26121627)
74. McKay, D. G.; Margaretten, W.; Csavossy, I. An electron microscope study of the effects of bacterial endotoxin on the blood-vascular system Lab. Invest. 1966, 15, 1815-1829
75. McCaffree, D. R.; Gray, B. A.; Pennock, B. E. Role of pulmonary edema in the acute pulmonary response to sepsis J. Appl. Physiol. 1981, 50, 1198-1205 (Pubitemid 11078934)
76. Olson, N.; Brown, T., Jr.; Anderson, D. Effect of polyethylene glycol-superoxide dismutase and catalase on endotoxemia in pigs J. Appl. Physiol. 1985, 58, 274-284
77. Meyrick, B.; Brigham, K. L. Acute effects of E. coli endotoxin on the pulmonary microcirculation of anesthetized sheep Lab. Invest. 1983, 48, 458-470 (Pubitemid 13119069)
78. Coalson, J. J.; Hinshaw, L. B.; Guenter, C. A. The pulmonary ultrastructure in septic shock Exp. Mol. Pathol. 1970, 12, 84-103
79. Burch, R. M.; Noronha-Blob, L.; Bator, J. M.; Lowe, V. C.; Sullivan, J. P. Mice treated with a leumedin or antibody to Mac-1 to inhibit leukocyte sequestration survive endotoxin challenge J. Immunol. 1993, 150, 3397-3403 (Pubitemid 23129718)
80. Golec, M. Cathelicidin LL-37: LPS-neutralizing, pleiotropic peptide Ann. Agric. Environ. Med. 2007, 14, 1-4 (Pubitemid 47035650)
81. Tralau-Stewart, C. J.; Williamson, R. A.; Nials, A. T.; Gascoigne, M.; Dawson, J.; Hart, G. J.; Angell, A. D. R.; Solanke, Y. E.; Lucas, F. S.; Wiseman, J.; Ward, P.; Ranshaw, L. E.; Knowles, R. G. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization J. Pharmacol. Exp. Ther. 2011, 337, 145-154
82. TM), in a rat model of pulmonary neutrophilia Pulm. Pharmacol. Ther. 2001, 14, 157-164 (Pubitemid 32553621)
83. Lefort, J.; Singer, M.; Leduc, D.; Renesto, P.; Nahori, M. A.; Huerre, M.; Créminon, C.; Chignard, M.; Vargaftig, B. B. Systemic administration of endotoxin induces bronchopulmonary hyperreactivity dissociated from TNF-alpha formation and neutrophil sequestration into the murine lungs J. Immunol. 1998, 161, 474-480 (Pubitemid 28285557)
84. Evers, A.; Klebe, G. Ligand-supported homology modeling of G-protein-coupled receptor sites: models sufficient for successful virtual screening Angew. Chem., Int. Ed. 2004, 43, 248-251 (Pubitemid 38082116)
85. Card, G. L.; England, B. P.; Suzuki, Y.; Fong, D.; Powell, B.; Lee, B.; Luu, C.; Tabrizizad, M.; Gillette, S.; Ibrahim, P. N.; Artis, D. R.; Bollag, G.; Milburn, M. V.; Kim, S. H.; Schlessinger, J.; Zhang, K. Y. Structural basis for the activity of drugs that inhibit phosphodiesterases Structure 2004, 12, 2233-2247 (Pubitemid 39593200)
86. Case, D. A.; Cheatham, T. E., III; Darden, T.; Gohlke, H.; Luo, R.; Merz, K. M., Jr.; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R. The Amber biomolecular simulation programs J. Comput. Chem. 2005, 26, 1668-1688 (Pubitemid 43076180)
87. Kagechika, H.; Himi, T.; Kawachi, E.; Shudo, K. Retinobenzoic acids. 4. Conformation of aromatic amides with retinoidal activity. Importance of trans -amide structure for the activity J. Med. Chem. 1989, 32, 2292-2296 (Pubitemid 19245889)
88. Kümmerle, A. E.; Vieira, M. M.; Schmitt, M.; Miranda, A. L.; Fraga, C. A.; Bourguignon, J.; Barreiro, E. J. Design, synthesis and analgesic properties of novel conformationally-restricted N -acylhydrazones (NAH) Bioorg. Med. Chem. Lett. 2009, 19, 4963-4966
89. Tobe, M.; Isobe, Y.; Tomizawa, H.; Nagasaki, T.; Takahashi, H.; Fukazawa, T.; Hayashi, H. Discovery of quinazolines as a novel structural class of potent inhibitors of NF-[kappa]B activation Bioorg. Med. Chem. 2003, 11, 383-391 (Pubitemid 36051028)
90. Gineinah, M. M.; Ismaiel, A. E. M.; El-Kerdawy, M. M.; Glennon, R. A. Mesoionic 1,2,4-triazolo[4,3-c]quinazolines J. Heterocycl. Chem. 1990, 27, 723-726 (Pubitemid 20193018)
91. Collot, V.; Dallemagne, P.; Bovy, P. R.; Rault, S. Suzuki-type cross-coupling reaction of 3-iodoindazoles with aryl boronic acids: A general and flexible route to 3-arylindazoles Tetrahedron 1999, 55, 6917-6922 (Pubitemid 29236675)
92. Böyum, A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g Scand. J. Clin. Lab. Invest. Suppl. 1968, 97, 77-89
93. Reimund, J. M.; Wittersheim, C.; Dumont, S.; Muller, C. D.; Kenney, J. S.; Baumann, R.; Poindron, P.; Duclos, B. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease Gut 1996, 39, 684-689 (Pubitemid 26426469)
94. Sybyl, Version 7.3. Tripos Associates: St. Louis, MO, 2007.
95. Halgren, T. A. Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions J. Comput. Chem. 1996, 17, 520-552 (Pubitemid 126567068)
96. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model J. Am. Chem. Soc. 1985, 107, 3902-3909